Literature DB >> 21417486

Pseudechis australis venomics: adaptation for a defense against microbial pathogens and recruitment of body transferrin.

Dessislava Georgieva1, Jana Seifert, Michaela Öhler, Martin von Bergen, Patrick Spencer, Raghuvir K Arni, Nicolay Genov, Christian Betzel.   

Abstract

The venom composition of Pseudechis australis, a widely distributed in Australia reptile, was analyzed by 2-DE and mass spectrometric analysis. In total, 102 protein spots were identified as venom toxins. The gel is dominated by horizontal trains of spots with identical or very similar molecular masses but differing in the pI values. This suggests possible post-translational modifications of toxins, changing their electrostatic charge. The results demonstrate a highly specialized biosynthesis of toxins destroying the hemostasis (P-III metalloproteases, SVMPs), antimicrobial proteins (L-amino acid oxidases, LAAOs, and transferrin-like proteins, TFLPs), and myotoxins (phospholipase A(2)s, PLA(2)s). The three transferrin isoforms of the Australian P. australis (Elapidae snake) venom are highly homologous to the body transferrin of the African Lamprophis fuliginosus (Colubridae), an indication for the recruitment of body transferrin. The venomic composition suggests an adaptation for a defense against microbial pathogens from the prey. Transferrins have not previously been reported as components of elapid or other snake venoms. Ecto-5'-nucleotidases (5'-NTDs), nerve growth factors (VNGFs), and a serine proteinase inhibitor (SPI) were also identified. The venom composition and enzymatic activities explain the clinical manifestation of the king brown snakebite. The results can be used for medical, scientific, and biotechnological purposes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21417486     DOI: 10.1021/pr101248e

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  7 in total

1.  Proteome Analysis of Toxic Fractions of Iranian Cobra (Naja naja Oxiana) Snake Venom Using Two-Dimensional Electrophoresis and Mass Spectrometry.

Authors:  M Samianifard; A Nazari; F Tahoori; N Mohamadpour Dounighi
Journal:  Arch Razi Inst       Date:  2021-03-01

Review 2.  Strategies in 'snake venomics' aiming at an integrative view of compositional, functional, and immunological characteristics of venoms.

Authors:  Bruno Lomonte; Juan J Calvete
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2017-04-28

3.  A pan-specific antiserum produced by a novel immunization strategy shows a high spectrum of neutralization against neurotoxic snake venoms.

Authors:  Kavi Ratanabanangkoon; Kae Yi Tan; Kritsada Pruksaphon; Chaiya Klinpayom; José María Gutiérrez; Naeem H Quraishi; Choo Hock Tan
Journal:  Sci Rep       Date:  2020-07-09       Impact factor: 4.379

4.  Analysis of Protein Composition and Bioactivity of Neoponera villosa Venom (Hymenoptera: Formicidae).

Authors:  Wallace Felipe Blohem Pessoa; Ludimilla Carvalho Cerqueira Silva; Leila de Oliveira Dias; Jacques Hubert Charles Delabie; Helena Costa; Carla Cristina Romano
Journal:  Int J Mol Sci       Date:  2016-04-21       Impact factor: 5.923

Review 5.  The Biochemical Toxin Arsenal from Ant Venoms.

Authors:  Axel Touchard; Samira R Aili; Eduardo Gonçalves Paterson Fox; Pierre Escoubas; Jérôme Orivel; Graham M Nicholson; Alain Dejean
Journal:  Toxins (Basel)       Date:  2016-01-20       Impact factor: 4.546

6.  Proteomic Investigations of Two Pakistani Naja Snake Venoms Species Unravel the Venom Complexity, Posttranslational Modifications, and Presence of Extracellular Vesicles.

Authors:  Aisha Manuwar; Benjamin Dreyer; Andreas Böhmert; Anwar Ullah; Zia Mughal; Ahmed Akrem; Syed Abid Ali; Hartmut Schlüter; Christian Betzel
Journal:  Toxins (Basel)       Date:  2020-10-22       Impact factor: 4.546

7.  Potency Testing of Venoms and Antivenoms in Embryonated Eggs: An Ethical Alternative to Animal Testing.

Authors:  Erin E Verity; Kathy Stewart; Kirsten Vandenberg; Chi Ong; Steven Rockman
Journal:  Toxins (Basel)       Date:  2021-03-24       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.